Persistent and aggressive treatment for thymic carcinoma : Results of a single-institute experience with 25 patients
The aim of this study is to retrospectively evaluate the role of several therapies, mainly chemotherapy, for thymic carcinoma (TC). From July 1973 to July 2005, 25 patients (15 males and 10 females) with histologically proven TC were treated at our department. The median age of the patients was 59 y...
Gespeichert in:
| Veröffentlicht in: | Oncology 2007-01, Vol.70 (5), p.325-329 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 329 |
|---|---|
| container_issue | 5 |
| container_start_page | 325 |
| container_title | Oncology |
| container_volume | 70 |
| creator | MARUYAMA, Riichiroh SUEMITSU, Ryuichi OKAMOTO, Tatsuro KOJO, Miyako AOKI, Yoshiro WATAYA, Hiroshi EGUCHI, Takashi NISHIYAMA, Kenichi SETO, Takashi ICHINOSE, Yukito |
| description | The aim of this study is to retrospectively evaluate the role of several therapies, mainly chemotherapy, for thymic carcinoma (TC).
From July 1973 to July 2005, 25 patients (15 males and 10 females) with histologically proven TC were treated at our department. The median age of the patients was 59 years, with a range of from 30 to 78 years. According to Masaoka's staging system, there was 1 stage I patient, 3 stage II, 7 stage III, 6 stage IVa, and 8 stage IVb patients. The histological subtype was in all cases squamous cell carcinoma, nonkeratinizing type.
There were 6 complete surgical resections, 1 incomplete resection followed by chemoradiotherapy, 6 with radiotherapy alone, 3 with radiotherapy plus chemotherapy, and 9 with chemotherapy alone as the initial treatment. Eighteen patients were administered second-line therapy. The regimen obtaining the best response rate was doublet chemotherapy consisting of carboplatin (CBDCA) and paclitaxel. The median survival time and survival rate at 5 years for the patients excluding surgical cases with stage I/II disease were 32 months and 31%, respectively.
The doublet of CBDCA and paclitaxel thus appears to be a promising regimen for TC and further investigation in a multi-institutional phase II trial is, therefore, strongly called for. |
| doi_str_mv | 10.1159/000097944 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68284497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1200974541</sourcerecordid><originalsourceid>FETCH-LOGICAL-p293t-f38cbdfc9d9a3261c2c01ceb84a285c75f5435029311d6331bb629f72c0afb6e3</originalsourceid><addsrcrecordid>eNqF0E2L1jAQB_Agivu4evALSBD0Vs17E2_L4hssKKLnkqaTZ7O0ac2k6n57Iz4ieHEuAzM_hj9DyGPOXnCu3UvWyvVOqTvkwJWQHRNS3CUHxiTrhOLqjDxAvGmq18rcJ2e850Zpaw-kfoSCCSvkSn2eqD8eCyCmb0BrAV-XX4u4Flqvb5cUaPAlpLwunr6inwD3uSJdI_UUUz7O0KWMNdW9AoUfG5QEOQD9nuo1FZpuvrZBxYfkXvQzwqNTPydf3rz-fPmuu_rw9v3lxVW3CSdrF6UN4xSDm5yXwvAgAuMBRqu8sDr0OmolNWuW88lIycfRCBf7xnwcDchz8vz33a2sX3fAOiwJA8yzz7DuOBgrrFKub_DpP_Bm3Utu2QYhmLXaqP8j0Tvb0JMT2scFpmErafHldvjz8QaenYDH4OdYfA4J_7oWyDBh5E9f845J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220885647</pqid></control><display><type>article</type><title>Persistent and aggressive treatment for thymic carcinoma : Results of a single-institute experience with 25 patients</title><source>MEDLINE</source><source>Karger Journals</source><creator>MARUYAMA, Riichiroh ; SUEMITSU, Ryuichi ; OKAMOTO, Tatsuro ; KOJO, Miyako ; AOKI, Yoshiro ; WATAYA, Hiroshi ; EGUCHI, Takashi ; NISHIYAMA, Kenichi ; SETO, Takashi ; ICHINOSE, Yukito</creator><creatorcontrib>MARUYAMA, Riichiroh ; SUEMITSU, Ryuichi ; OKAMOTO, Tatsuro ; KOJO, Miyako ; AOKI, Yoshiro ; WATAYA, Hiroshi ; EGUCHI, Takashi ; NISHIYAMA, Kenichi ; SETO, Takashi ; ICHINOSE, Yukito</creatorcontrib><description>The aim of this study is to retrospectively evaluate the role of several therapies, mainly chemotherapy, for thymic carcinoma (TC).
From July 1973 to July 2005, 25 patients (15 males and 10 females) with histologically proven TC were treated at our department. The median age of the patients was 59 years, with a range of from 30 to 78 years. According to Masaoka's staging system, there was 1 stage I patient, 3 stage II, 7 stage III, 6 stage IVa, and 8 stage IVb patients. The histological subtype was in all cases squamous cell carcinoma, nonkeratinizing type.
There were 6 complete surgical resections, 1 incomplete resection followed by chemoradiotherapy, 6 with radiotherapy alone, 3 with radiotherapy plus chemotherapy, and 9 with chemotherapy alone as the initial treatment. Eighteen patients were administered second-line therapy. The regimen obtaining the best response rate was doublet chemotherapy consisting of carboplatin (CBDCA) and paclitaxel. The median survival time and survival rate at 5 years for the patients excluding surgical cases with stage I/II disease were 32 months and 31%, respectively.
The doublet of CBDCA and paclitaxel thus appears to be a promising regimen for TC and further investigation in a multi-institutional phase II trial is, therefore, strongly called for.</description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000097944</identifier><identifier>PMID: 17164588</identifier><language>eng</language><publisher>Basel: Karger</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer ; Carboplatin - administration & dosage ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - radiotherapy ; Carcinoma, Squamous Cell - therapy ; Chemotherapy ; Chemotherapy, Adjuvant ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Oncology ; Paclitaxel - administration & dosage ; Pneumology ; Radiation ; Radiotherapy, Adjuvant ; Retrospective Studies ; Surgery ; Survival Analysis ; Thymoma - drug therapy ; Thymoma - radiotherapy ; Thymoma - therapy ; Thymus Neoplasms - drug therapy ; Thymus Neoplasms - radiotherapy ; Thymus Neoplasms - therapy ; Treatment Outcome ; Tumors ; Tumors of the respiratory system and mediastinum</subject><ispartof>Oncology, 2007-01, Vol.70 (5), p.325-329</ispartof><rights>2007 INIST-CNRS</rights><rights>Copyright 2006 S. Karger AG, Basel.</rights><rights>Copyright National Library of Medicine - MEDLINE Abstracts 2006</rights><rights>Copyright S. Karger AG Jan 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27913,27914</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18446026$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17164588$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MARUYAMA, Riichiroh</creatorcontrib><creatorcontrib>SUEMITSU, Ryuichi</creatorcontrib><creatorcontrib>OKAMOTO, Tatsuro</creatorcontrib><creatorcontrib>KOJO, Miyako</creatorcontrib><creatorcontrib>AOKI, Yoshiro</creatorcontrib><creatorcontrib>WATAYA, Hiroshi</creatorcontrib><creatorcontrib>EGUCHI, Takashi</creatorcontrib><creatorcontrib>NISHIYAMA, Kenichi</creatorcontrib><creatorcontrib>SETO, Takashi</creatorcontrib><creatorcontrib>ICHINOSE, Yukito</creatorcontrib><title>Persistent and aggressive treatment for thymic carcinoma : Results of a single-institute experience with 25 patients</title><title>Oncology</title><addtitle>Oncology</addtitle><description>The aim of this study is to retrospectively evaluate the role of several therapies, mainly chemotherapy, for thymic carcinoma (TC).
From July 1973 to July 2005, 25 patients (15 males and 10 females) with histologically proven TC were treated at our department. The median age of the patients was 59 years, with a range of from 30 to 78 years. According to Masaoka's staging system, there was 1 stage I patient, 3 stage II, 7 stage III, 6 stage IVa, and 8 stage IVb patients. The histological subtype was in all cases squamous cell carcinoma, nonkeratinizing type.
There were 6 complete surgical resections, 1 incomplete resection followed by chemoradiotherapy, 6 with radiotherapy alone, 3 with radiotherapy plus chemotherapy, and 9 with chemotherapy alone as the initial treatment. Eighteen patients were administered second-line therapy. The regimen obtaining the best response rate was doublet chemotherapy consisting of carboplatin (CBDCA) and paclitaxel. The median survival time and survival rate at 5 years for the patients excluding surgical cases with stage I/II disease were 32 months and 31%, respectively.
The doublet of CBDCA and paclitaxel thus appears to be a promising regimen for TC and further investigation in a multi-institutional phase II trial is, therefore, strongly called for.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Pneumology</subject><subject>Radiation</subject><subject>Radiotherapy, Adjuvant</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Survival Analysis</subject><subject>Thymoma - drug therapy</subject><subject>Thymoma - radiotherapy</subject><subject>Thymoma - therapy</subject><subject>Thymus Neoplasms - drug therapy</subject><subject>Thymus Neoplasms - radiotherapy</subject><subject>Thymus Neoplasms - therapy</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0E2L1jAQB_Agivu4evALSBD0Vs17E2_L4hssKKLnkqaTZ7O0ac2k6n57Iz4ieHEuAzM_hj9DyGPOXnCu3UvWyvVOqTvkwJWQHRNS3CUHxiTrhOLqjDxAvGmq18rcJ2e850Zpaw-kfoSCCSvkSn2eqD8eCyCmb0BrAV-XX4u4Flqvb5cUaPAlpLwunr6inwD3uSJdI_UUUz7O0KWMNdW9AoUfG5QEOQD9nuo1FZpuvrZBxYfkXvQzwqNTPydf3rz-fPmuu_rw9v3lxVW3CSdrF6UN4xSDm5yXwvAgAuMBRqu8sDr0OmolNWuW88lIycfRCBf7xnwcDchz8vz33a2sX3fAOiwJA8yzz7DuOBgrrFKub_DpP_Bm3Utu2QYhmLXaqP8j0Tvb0JMT2scFpmErafHldvjz8QaenYDH4OdYfA4J_7oWyDBh5E9f845J</recordid><startdate>200701</startdate><enddate>200701</enddate><creator>MARUYAMA, Riichiroh</creator><creator>SUEMITSU, Ryuichi</creator><creator>OKAMOTO, Tatsuro</creator><creator>KOJO, Miyako</creator><creator>AOKI, Yoshiro</creator><creator>WATAYA, Hiroshi</creator><creator>EGUCHI, Takashi</creator><creator>NISHIYAMA, Kenichi</creator><creator>SETO, Takashi</creator><creator>ICHINOSE, Yukito</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9-</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200701</creationdate><title>Persistent and aggressive treatment for thymic carcinoma : Results of a single-institute experience with 25 patients</title><author>MARUYAMA, Riichiroh ; SUEMITSU, Ryuichi ; OKAMOTO, Tatsuro ; KOJO, Miyako ; AOKI, Yoshiro ; WATAYA, Hiroshi ; EGUCHI, Takashi ; NISHIYAMA, Kenichi ; SETO, Takashi ; ICHINOSE, Yukito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p293t-f38cbdfc9d9a3261c2c01ceb84a285c75f5435029311d6331bb629f72c0afb6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Pneumology</topic><topic>Radiation</topic><topic>Radiotherapy, Adjuvant</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Survival Analysis</topic><topic>Thymoma - drug therapy</topic><topic>Thymoma - radiotherapy</topic><topic>Thymoma - therapy</topic><topic>Thymus Neoplasms - drug therapy</topic><topic>Thymus Neoplasms - radiotherapy</topic><topic>Thymus Neoplasms - therapy</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MARUYAMA, Riichiroh</creatorcontrib><creatorcontrib>SUEMITSU, Ryuichi</creatorcontrib><creatorcontrib>OKAMOTO, Tatsuro</creatorcontrib><creatorcontrib>KOJO, Miyako</creatorcontrib><creatorcontrib>AOKI, Yoshiro</creatorcontrib><creatorcontrib>WATAYA, Hiroshi</creatorcontrib><creatorcontrib>EGUCHI, Takashi</creatorcontrib><creatorcontrib>NISHIYAMA, Kenichi</creatorcontrib><creatorcontrib>SETO, Takashi</creatorcontrib><creatorcontrib>ICHINOSE, Yukito</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MARUYAMA, Riichiroh</au><au>SUEMITSU, Ryuichi</au><au>OKAMOTO, Tatsuro</au><au>KOJO, Miyako</au><au>AOKI, Yoshiro</au><au>WATAYA, Hiroshi</au><au>EGUCHI, Takashi</au><au>NISHIYAMA, Kenichi</au><au>SETO, Takashi</au><au>ICHINOSE, Yukito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Persistent and aggressive treatment for thymic carcinoma : Results of a single-institute experience with 25 patients</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>2007-01</date><risdate>2007</risdate><volume>70</volume><issue>5</issue><spage>325</spage><epage>329</epage><pages>325-329</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract>The aim of this study is to retrospectively evaluate the role of several therapies, mainly chemotherapy, for thymic carcinoma (TC).
From July 1973 to July 2005, 25 patients (15 males and 10 females) with histologically proven TC were treated at our department. The median age of the patients was 59 years, with a range of from 30 to 78 years. According to Masaoka's staging system, there was 1 stage I patient, 3 stage II, 7 stage III, 6 stage IVa, and 8 stage IVb patients. The histological subtype was in all cases squamous cell carcinoma, nonkeratinizing type.
There were 6 complete surgical resections, 1 incomplete resection followed by chemoradiotherapy, 6 with radiotherapy alone, 3 with radiotherapy plus chemotherapy, and 9 with chemotherapy alone as the initial treatment. Eighteen patients were administered second-line therapy. The regimen obtaining the best response rate was doublet chemotherapy consisting of carboplatin (CBDCA) and paclitaxel. The median survival time and survival rate at 5 years for the patients excluding surgical cases with stage I/II disease were 32 months and 31%, respectively.
The doublet of CBDCA and paclitaxel thus appears to be a promising regimen for TC and further investigation in a multi-institutional phase II trial is, therefore, strongly called for.</abstract><cop>Basel</cop><pub>Karger</pub><pmid>17164588</pmid><doi>10.1159/000097944</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-2414 |
| ispartof | Oncology, 2007-01, Vol.70 (5), p.325-329 |
| issn | 0030-2414 1423-0232 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68284497 |
| source | MEDLINE; Karger Journals |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer Carboplatin - administration & dosage Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - therapy Chemotherapy Chemotherapy, Adjuvant Female Follow-Up Studies Humans Male Medical sciences Middle Aged Neoplasm Staging Oncology Paclitaxel - administration & dosage Pneumology Radiation Radiotherapy, Adjuvant Retrospective Studies Surgery Survival Analysis Thymoma - drug therapy Thymoma - radiotherapy Thymoma - therapy Thymus Neoplasms - drug therapy Thymus Neoplasms - radiotherapy Thymus Neoplasms - therapy Treatment Outcome Tumors Tumors of the respiratory system and mediastinum |
| title | Persistent and aggressive treatment for thymic carcinoma : Results of a single-institute experience with 25 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T09%3A34%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Persistent%20and%20aggressive%20treatment%20for%20thymic%20carcinoma%20:%20Results%20of%20a%20single-institute%20experience%20with%2025%20patients&rft.jtitle=Oncology&rft.au=MARUYAMA,%20Riichiroh&rft.date=2007-01&rft.volume=70&rft.issue=5&rft.spage=325&rft.epage=329&rft.pages=325-329&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000097944&rft_dat=%3Cproquest_pubme%3E1200974541%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220885647&rft_id=info:pmid/17164588&rfr_iscdi=true |